Market and Product Forecasts: HER2-Negative/Hormone Receptor-Positive Breast Cancer - Patent expiries and novel drugs shape the market in the next decade

• Publication date: July 2012
• Report size: 41 pages

The treatment of HER2-negative/hormone receptor-positive breast cancer consists largely of genericized cytotoxic and antihormonal therapies. Avastin (bevacizumab) is currently the only targeted therapy used in this patient population. Patent expiries and the uptake of novel targeted drugs will help shape the market in the next decade, but little change is anticipated in the overall market value....

The treatment of HER2-negative/hormone receptor-positive breast cancer consists largely of genericized cytotoxic and antihormonal therapies. Avastin (bevacizumab) is currently the only targeted therapy used in this patient population. Patent expiries and the uptake of novel targeted drugs will help shape the market in the next decade, but little change is anticipated in the overall market value.Analysis of HER2-negative/hormone receptor-positive breast cancer drugs in the seven major marketsPatient based sales forecast for drugs in the HER2-negative/hormone receptor-positive breast cancer market from 2011 to 2020In depth analysis of the factors influencing the HER2-negative/hormone receptor-positive breast cancer drug sales in the seven major marketsMolecule dynamics and assessment of the key HER2-negative/hormone receptor-positive breast cancer drugs in the seven major marketsThe HER2-/HR+ breast cancer market will experience a modest decrease in sales over the forecast period. The value of the market is forecast to decrease from nearly $5.0bn in 2011 to about $4.7bn in 2020 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK), representing a CAGR of -0.69%.The patent expiry of Xeloda will have a big impact on the value of the market. Xeloda (capecitabine; Genentech/Roche/Chugai) is forecast to be the highest-selling chemotherapy in the HER2-negative/hormone receptor-positive breast cancer market in 2012, with sales of over $650m in the seven major markets.Novel targeted therapies will gain a small share of the market. Three novel targeted therapies – Novartis’s Afinitor (everolimus), Bayer Schering/Onyx’s Nexavar (sorafenib), and Eli Lilly’s ramucirumab – are expected to enter the HER2-negative/hormone receptor-positive breast cancer market within the forecast period.Quantify the performance of each of HER2-/HR+ breast cancer drug in the seven major markets by molecule and regimen sales.Gain insight into the key trends in individual HER2-/HR+ breast cancer markets across the seven major markets.The report is accompanied by a PowerPoint presentation and Excel deliverable showing full HER2-/HR+ breast cancer forecasts for the US, Japan and 5EU.

Pathology Industry